ダウンロード数: 355
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s10096-011-1523-4.pdf | 362.27 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Matsumura, Y | en |
dc.contributor.author | Yamamoto, M | en |
dc.contributor.author | Matsushima, A | en |
dc.contributor.author | Nagao, M | en |
dc.contributor.author | Ito, Y | en |
dc.contributor.author | Takakura, S | en |
dc.contributor.author | Ichiyama, S | en |
dc.contributor.alternative | 松村, 康史 | ja |
dc.date.accessioned | 2013-08-19T07:25:30Z | - |
dc.date.available | 2013-08-19T07:25:30Z | - |
dc.date.issued | 2012-08-01 | - |
dc.identifier.issn | 0934-9723 | - |
dc.identifier.uri | http://hdl.handle.net/2433/178037 | - |
dc.description.abstract | We investigated the performance of cefotaxime for the detection of extended-spectrum β-lactamase (ESBL) or plasmid-mediated AmpC β-lactamase (pAmpC) and the clinical characteristics of cefotaxime-non-susceptible Escherichia coli or Klebsiella pneumoniae (CTXNS-EK) bacteraemia. All of the consecutive bloodstream isolates between 2005 and 2010 in a Japanese university hospital were characterised using polymerase chain reaction (PCR). Risk factors and outcomes of CTXNS-EK were analysed by multivariate logistic regression analysis. We identified 58 CTXNS-EK (15.6%) from 249 E. coli and 122 K. pneumoniae. Cefotaxime with a minimum inhibitory concentration (MIC) of >1 μg/mL had a sensitivity of 98.3% and a specificity of 99.7% for the detection of ESBL or pAmpC. CTXNS-EK had increased from 4.5% in 2005 to 23% in 2009. Risk factors for CTXNS-EK were previous isolation of multidrug-resistant bacteria, use of oxyimino-cephalosporins or fluoroquinolones, and high Sequential Organ Failure Assessment (SOFA) score. Patients with CTXNS-EK bacteraemia less frequently received appropriate empirical therapy than patients with cefotaxime-susceptible EK bacteraemia (81% vs. 97%, p<0.001) and died within 30 days (21% vs. 5%, p=0.001). Using the current breakpoints of the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST), cefotaxime alone can identify ESBL or pAmpC producers. CTXNS-EK is an important and increasingly prevalent bacteraemia pathogen. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer-Verlag | en |
dc.rights | The final publication is available at link.springer.com | en |
dc.rights | この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 | ja |
dc.rights | This is not the published version. Please cite only the published version. | en |
dc.subject | cefotaxime | en |
dc.subject | bloodstream infection | en |
dc.subject | risk factor | en |
dc.subject | prognosis | en |
dc.subject | ESBL | en |
dc.subject | AmpC | en |
dc.subject.mesh | Aged | en |
dc.subject.mesh | Anti-Bacterial Agents/pharmacology | en |
dc.subject.mesh | Bacteremia/microbiology | en |
dc.subject.mesh | Bacteremia/pathology | en |
dc.subject.mesh | Cefotaxime/pharmacology | en |
dc.subject.mesh | Cohort Studies | en |
dc.subject.mesh | DNA, Bacterial/genetics | en |
dc.subject.mesh | Escherichia coli/drug effects | en |
dc.subject.mesh | Escherichia coli/enzymology | en |
dc.subject.mesh | Escherichia coli/isolation & purification | en |
dc.subject.mesh | Escherichia coli Infections/microbiology | en |
dc.subject.mesh | Escherichia coli Infections/pathology | en |
dc.subject.mesh | Female | en |
dc.subject.mesh | Hospitals, University | en |
dc.subject.mesh | Humans | en |
dc.subject.mesh | Japan | en |
dc.subject.mesh | Klebsiella Infections/microbiology | en |
dc.subject.mesh | Klebsiella Infections/pathology | en |
dc.subject.mesh | Klebsiella pneumoniae/drug effects | en |
dc.subject.mesh | Klebsiella pneumoniae/enzymology | en |
dc.subject.mesh | Klebsiella pneumoniae/isolation & purification | en |
dc.subject.mesh | Male | en |
dc.subject.mesh | Microbial Sensitivity Tests/methods | en |
dc.subject.mesh | Middle Aged | en |
dc.subject.mesh | Polymerase Chain Reaction | en |
dc.subject.mesh | Retrospective Studies | en |
dc.subject.mesh | Risk Factors | en |
dc.subject.mesh | Sensitivity and Specificity | en |
dc.subject.mesh | Treatment Outcome | en |
dc.subject.mesh | beta-Lactamases/analysis | en |
dc.title | Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia. | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | European journal of clinical microbiology & infectious diseases | en |
dc.identifier.volume | 31 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 1931 | - |
dc.identifier.epage | 1939 | - |
dc.relation.doi | 10.1007/s10096-011-1523-4 | - |
dc.textversion | author | - |
dc.identifier.pmid | 22210267 | - |
dcterms.accessRights | open access | - |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。